Gary I. Cohen

2.9k total citations
40 papers, 1.7k citations indexed

About

Gary I. Cohen is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Gary I. Cohen has authored 40 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Gary I. Cohen's work include CAR-T cell therapy research (9 papers), Cutaneous Melanoma Detection and Management (6 papers) and Virus-based gene therapy research (4 papers). Gary I. Cohen is often cited by papers focused on CAR-T cell therapy research (9 papers), Cutaneous Melanoma Detection and Management (6 papers) and Virus-based gene therapy research (4 papers). Gary I. Cohen collaborates with scholars based in United States, Canada and Mexico. Gary I. Cohen's co-authors include John M. Kirkwood, Charles Lee, Michael B. Atkins, Lawrence E. Flaherty, Vernon K. Sondak, Jeffrey A. Sosman, Jessie J. Hsu, Andrew L. Pecora, Victoria Mock and Mary Pickett and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Gary I. Cohen

36 papers receiving 1.6k citations

Peers

Countries citing papers authored by Gary I. Cohen

Since Specialization

Citations

This map shows the geographic impact of Gary I. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary I. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary I. Cohen more than expected).

Fields of papers citing papers by Gary I. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary I. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary I. Cohen. The network helps show where Gary I. Cohen may publish in the future.

Co-authorship network of co-authors of Gary I. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Gary I. Cohen. A scholar is included among the top collaborators of Gary I. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary I. Cohen. Gary I. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA56 ECOG-ACRIN EA6174: STAMP: Surgically treated adjuvant merkel cell carcinoma with pembrolizumab, a phase III trial 2025 ·Annals of Oncology ·Janice M. Mehnert, Sung Jae Lee, (unknown), Chao‐Chin Hsu, Gary I. Cohen, Donald M. Eicher, Pauline Funchain, Ann W. Silk, David Miller, (unknown), Jedd D. Wolchok, (unknown), (unknown)	0
2	Retrospective case-control analysis of the infectious complications of retained broken needles in people who inject drugs 2025 ·Medicine ·(unknown), (unknown), (unknown), Daohai Yu, Xiaoning Lu, (unknown), Gary I. Cohen, Hillel S. Maresky	0
3	DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results. 2025 ·Journal of Clinical Oncology ·M.B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Geoffrey T. Gibney, (unknown), Diwakar Davar, Joe Stephenson, Brendan D. Curti, Joanna M. Brell, Kari Kendra, Alexandra P. Ikeguchi, (unknown), Samantha Guild, Jedd D. Wolchok, Antoni Ribas, John M. Kirkwood	0
4	Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609 2022 ·Quality of Life Research ·Laurie E. McLouth, Yue Zheng, Stephanie A. Smith, F. Stephen Hodi, Uma N. M. Rao, Gary I. Cohen, Thomas Amatruda, Shaker R. Dakhil, Brendan D. Curti, (unknown), Sreenivasa R Chandana, Charles Bane, (unknown), Sandra J. Lee, Vernon K. Sondak, John M. Kirkwood, Ahmad A. Tarhini, Lynne I. Wagner	4
5	The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote 2021 ·Journal of Cancer Survivorship ·(unknown), Cesar A. Santa‐Maria, Amanda L. Blackford, (unknown), Ashley Carpenter, Karen L. Smith, Gary I. Cohen, Janelle W. Coughlin, Lawrence J. Appel, Vered Stearns, Claire Snyder	6
6	Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant Ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): Health-related quality of life (HRQL) analysis of ECOG-ACRIN E1609. 2020 ·Journal of Clinical Oncology ·Ahmad A. Tarhini, Yue Zheng, Sandra J. Lee, F. Stephen Hodi, Uma Rao, Gary I. Cohen, Vernon K. Sondak, John M. Kirkwood, Lynne I. Wagner	1
7	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697) 2017 ·Clinical Cancer Research ·Lisa H. Butterfield, Fengmin Zhao, Charles Lee, Ahmad A. Tarhini, Kim Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood, David H. Lawson	35
8	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697) 2015 ·Journal of Clinical Oncology ·David H. Lawson, Charles Lee, Fengmin Zhao, Ahmad A. Tarhini, Kim Margolin, Marc S. Ernstoff, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, Lisa H. Butterfield, John M. Kirkwood	90
9	Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma 2011 ·Cancer ·(unknown), James E. Liebmann, Manuel Modiano, Gary I. Cohen, Barbara Pro, Jorge Romaguera, (unknown), Jack W. Singer, Luis Fayad	16
10	Exercise manages fatigue during breast cancer treatment: A randomized controlled trial 2004 ·Psycho-Oncology ·Victoria Mock, Constantine Frangakis, Nancy E. Davidson, Mary E. Ropka, Mary Pickett, (unknown), Kerry J. Stewart, (unknown), (unknown), Laura Jean Podewils, Gary I. Cohen, Ruth McCorkle	299
11	Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL). 2004 ·Blood ·Luis Fayad, James Liebmann, Manuel Modiano, Gary I. Cohen, Barbara Pro, Jorge Romaguera, Cristina Davite, (unknown), Silvia Comis, B. Laffranchi	3
12	The Satisfaction with Life Domains Scale for Breast Cancer (SLDS-BC) 2003 ·The Breast Journal ·(unknown), James Zabora, Karlynn BrintzenhofeSzoc, Craig M. Hooker, Gary I. Cohen, Frank Baker	44
13	Clinical Research by Community Oncologists 2003 ·CA A Cancer Journal for Clinicians ·Gary I. Cohen	22
14	Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer 2002 ·Annals of Oncology ·Frankie A. Holmes, Stephen E. Jones, Joyce O’Shaughnessy, Svetislava J. Vukelja, Timothy George, Michael A. Savin, Donald Richards, John A. Glaspy, Luís Meza, Gary I. Cohen, Mandeep S. Dhami, Daniel R. Budman, James Hackett, Marc-André Brassard, Bingbing Yang, Bertrand C. Liang	241
15	Chemotherapy-Induced Menopause: A Literature Review 2001 ·Cancer Investigation ·(unknown), Patricia M. Grimm, Gary I. Cohen	27
16	Sheathless Technique of Ash Split-Cath Insertion 2001 ·Journal of Vascular and Interventional Radiology ·Aalpen A. Patel, (unknown), David S. Ball, Gary I. Cohen, Douglas C. Smith	12
17	A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy 1999 ·Supportive Care in Cancer ·Burton Needles, Eduardo Miranda, (unknown), (unknown), Jesse I. Spector, (unknown), Gary I. Cohen, Steven H. Krasnow, (unknown), Michael Ames	7
18	Blood pressure and body mass index in Ethiopian immigrants: comparison of operations Solomon and Moses. 1993 ·PubMed ·(unknown), Uri Goldbourt, (unknown), (unknown), Gary I. Cohen, Yael Villa	2
19	Role of stromal and hematopoietic stem cells in Friend spleen focus forming virus effects in continuous bone marrow culture 1983 ·Leukemia Research ·Joel S. Greenberger, Robert J. Eckner, Mary Ann Sakakeeny, Gary I. Cohen	11
20	A phase II study of dihydroxyanthracenedione (DHAD) 1982 ·Proceedings of the American Association for Cancer Research ·Kenneth C. Anderson, Gary I. Cohen, Marc B. Garnick	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact